The invention provides a treatment of mesothelioma, especially malignant pleural mesothelioma, using an estrogen receptor ß subtype (ERß) agonist, wherein the treatment comprises administering the ERß agonist to the patient, and then after a time, t, of up to 24 hours administering a platinum-containing anti-cancer drug to the patient. The invention also provides an ERß agonist and a platinum-containing anti-cancer drug for use in the treatment of mesothelioma in a patient, wherein the treatment comprises administering the ERß agonist to the patient, and then after a time, t, of up to 24 hours, administering the platinum- containing anti-cancer drug to the patient and a kit comprising a platinum-containing anti- cancer drug and an ERß agonist.
